After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
Kalaris to go public via reverse merger with AlloVir
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
